VPHM Share Price

Open 49.98 Change Price %
High 50.01 1 Day -0.01 -0.02
Low 49.96 1 Week 0.00 0.00
Close 49.96 1 Month 0.00 0.00
Volume 4776453 1 Year 0.00 0.00
52 Week High 6.25
52 Week Low 2.47
VPHM Important Levels
Resistance 2 50.01
Resistance 1 49.99
Pivot 49.98
Support 1 49.93
Support 2 49.91
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

ViroPharma Incorporated (NASDAQ: VPHM)

VPHM Technical Analysis 5
As on 23rd Jan 2014 VPHM Share Price closed @ 49.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 34.43 & Strong Buy for SHORT-TERM with Stoploss of 48.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
VPHM Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
VPHM Other Details
Segment EQ
Market Capital 1670772992.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
VPHM Address
VPHM
N/A
VPHM Latest News
Shire makes yet another move on its local office space   Philadelphia Business Journal (blog)   - 09th Jul 15
On 'Bordeaux' of phase III, Meritage finds Shire buyer: $70M up front for EoE drug   BioWorld Online   - 25th Feb 15
Shire to Buy NPS for $5.2 Billion for Rare-Disease Drugs   Bloomberg   - 11th Jan 15
As big pharma moves to Mass., workers feel squeeze   Boston Globe   - 06th Jan 15
Shire Makes Its Case Against a Deal With AbbVie   New York Times   - 23rd Jun 14
$4.2 billion deal gives ViroPharma execs huge paydays   Philadelphia Business Journal (blog)   - 06th Feb 14
Inside the deal: Shire's $4.2B acquisition of ViroPharma   Philadelphia Business Journal (blog)   - 27th Nov 13
ViroPharma surges, Shire settles as investors digest $4.2 billion merger   MarketWatch (blog)   - 11th Nov 13
Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug   Bloomberg   - 11th Nov 13
Making Sense of the Drama About ViroPharma   Motley Fool   - 16th Sep 13
Interactive Technical Analysis Chart ViroPharma Incorporated ( VPHM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ViroPharma Incorporated
VPHM Business Profile
ViroPharma Incorporated (ViroPharma) is an international biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). The Company is also developing VP20621 for the treatment and prevention of CDAD.